Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-12-16 | Margaret G. McGlynn is the retired President and Chief Executive Officer of International AIDS Vaccine Initiative. ... Director of the Company since 2005. ... For fiscal year 2015, directors who were not employed by the Company received an annual cash retainer for Board service of $100,000. ... The 2015 Director Compensation table shows Margaret G. McGlynn received total compensation of $253,074. |
| 2016-12-14 | Margaret G. McGlynn is the retired President and Chief Executive Officer of International AIDS Vaccine Initiative, a global not-for-profit, public-private partnership working to accelerate the development of vaccines to prevent HIV infection and AIDS. ... Ms. McGlynn previously served as President, Global Vaccine and Infectious Disease Division of Merck & Co., Inc., a global pharmaceutical company, from 2007 until her retirement in 2009. ... For fiscal year 2016, directors who were not employed by the Company received an annual cash retainer for Board service of $100,000. Committee chairs received an additional retainer of $15,000 and the Lead Director received an additional annual retainer of $20,000. Meeting fees of $2,000 per meeting were paid for participating in committee meetings. ... 2016 Director Compensation ... M. G. McGlynn ... $112,000 Fees Earned or Paid in Cash ... $120,081 Stock Awards ... Total $237,081. |
| 2017-12-13 | MARGARET G. McGLYNN, age 58. Retired President, International AIDS Vaccine Initiative and Merck & Co., Inc. Global Vaccine and Infectious Disease Division. Director of the Company since 2005. ... Ms. McGlynn brings extensive experience in government relations and public policy, international marketing, mergers and acquisitions and talent management. ... The Board has three standing committees ... Margaret G. McGlynn serves on Audit and Finance and Corporate Governance and Nominating committees. ... 2017 Director Compensation ... M. G. McGlynn total compensation $235,090. |
| 2018-12-12 | Margaret G. McGlynn is the retired President of the Global Vaccine and Infectious Disease Division of Merck & Co., a global pharmaceutical company, where she worked for 26 years until her retirement in 2009. Following retirement, she served as President and Chief Executive Officer of International AIDS Vaccine Initiative, a global not-for-profit, public-private partnership working to accelerate the development of vaccines to prevent HIV infection and AIDS. She joined its board in 2010 and served as President and Chief Executive Officer from 2011 until her retirement in 2015. As President, Global Vaccine and Infectious Disease Division of Merck & Co., Inc., from 2006 until her retirement in 2009, she was responsible for a portfolio of more than $7 billion in global sales. She led the introduction of several new vaccine products and anti-infective therapies, expanded Mercks vaccine and infectious disease business globally and launched several initiatives to provide access to its vaccines and HIV therapies in the developing world. She also led several other divisions, including U.S. Human Health and Hospital and Specialty Products and Global Marketing. Ms. McGlynn is a director of Amicus Therapeutics, Inc. and Vertex Pharmaceuticals, Inc. She formerly served as a director of Quidel Diagnostics. She earned a Bachelors degree in Pharmacy and a Masters of Business Administration in Marketing from State University of New York at Buffalo. Age 59. Committees: Corporate Governance and Nominating, Management Development and Compensation. Fiscal 2018 total compensation: $260,162. |
| 2019-12-11 | Margaret G. McGlynn is retired President of Merck & Co., Inc. Global Vaccine and Infectious Disease Division... Age 60... Committees: Corporate Governance and Nominating, Management Development and Compensation... Fiscal 2019 Director Compensation: 260,140 USD. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-27 | Ms. McGlynn has significant leadership experience in the pharmaceutical industry, including her service as a senior executive of Merck where she led commercialization across several therapeutic areas and geographies. |
| 2019-04-29 | Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo. |
| 2020-04-24 | Ms. McGlynn holds a B.S. in Pharmacy and a M.B.A. in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo. |
| 2021-04-27 | Margaret G. McGlynn has served as a member of the Board since October 2009. She retired from Merck after 26 years including roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as Chief Executive Officer and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as a member of the Boards of Directors of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) and Novavax, Inc. (NASDAQ: NVAX). Previously, she served on the Boards of Air Products and Chemicals, Inc. (NYSE: APD) and Orphan Technologies. She is also Chair of the Board of HCU Network America, a non-profit which provides advocacy and supports research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a M.B.A. in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo. |
| 2022-04-26 | Ms. McGlynn holds a B.S. in Pharmacy and a M.B.A. in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo. |
| 2023-04-26 | Ms. McGlynn holds a B.S. in Pharmacy and a M.B.A. in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo. |
| 2024-04-24 | Ms. McGlynn holds a B.S. in Pharmacy and a M.B.A. in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo. |
Data sourced from SEC filings. Last updated: 2026-02-03